Addendum

Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60

Report documents

Indication:

Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to prior disease-modifying antirheumatic therapy

Result of dossier assessment:

Patients who have had an inadequate response or who have been intolerant to prior conventional disease-modifying antirheumatic therapy:Unchanged after addendum: added benefit not proven
Patients who have had an inadequate response or who have been intolerant to prior therapy with biologic disease-modifying antirheumatic drugs:Unchanged after addendum: added benefit not proven

2023-12-21 A G-BA decision was published.

Project no.: A23-105
Commission: Commission awarded on 07.11.2023 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://dx.doi.org/10.60584/A23-105

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.